Avoro Capital Advisors Trims Stake in BioCryst Pharmaceuticals

Institutional investor reduces position in biotech company by over 70%

Mar. 14, 2026 at 7:06am

Got story updates? Submit your updates here. ›

Avoro Capital Advisors LLC, an institutional investor, has reduced its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 72.2% in the third quarter, according to a recent 13F filing with the Securities and Exchange Commission (SEC). The firm now owns 1,250,000 shares of the biotechnology company's stock, down from 4,500,000 shares previously.

Why it matters

This reduction in Avoro Capital's position in BioCryst Pharmaceuticals is noteworthy as the firm was previously a major shareholder in the company. The move could signal a shift in Avoro's investment strategy or outlook on BioCryst's prospects, which could impact the stock price and investor sentiment.

The details

According to the 13F filing, Avoro Capital Advisors sold 3,250,000 shares of BioCryst Pharmaceuticals during the third quarter. The firm now owns approximately 0.59% of the biotechnology company's outstanding shares, down from a previous stake of over 2%. BioCryst Pharmaceuticals is the 28th largest holding in Avoro Capital's portfolio.

  • Avoro Capital Advisors reduced its position in BioCryst Pharmaceuticals during the third quarter of 2026.

The players

Avoro Capital Advisors LLC

An institutional investment firm that has reduced its stake in BioCryst Pharmaceuticals by over 70%.

BioCryst Pharmaceuticals, Inc.

A clinical-stage biotechnology company focused on the discovery and development of novel, oral small-molecule medicines for rare and serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Avoro Capital's significant reduction in its position in BioCryst Pharmaceuticals could signal a shift in the firm's investment strategy or outlook on the biotech company's prospects. This move may impact the stock price and investor sentiment surrounding BioCryst going forward.